An antibody is a protein made by immune cells that is of or specific shape and size so that it can attach itself to a specific point on a particular foreign substance, such as a virus or bacteria. By attaching, the antibody can potentially prevent these invaders from causing an infection. An antibody cocktail is a therapy which is a cocktail of two antibodies, which are basically the proteins that body generates to defend or protect itself against any disease. For example, monoclonal antibody cocktail of the antibodies Casirivimab and Imdevmab has proven to show positive results for recovering faster from COVID-19 infection.
The global antibody cocktails market was valued at US$ 2,113.5 million in 2021 and is expected to exhibit a CAGR of 10.9% during the forecast period (2021-2028).
Figure 1. Global Antibody Cocktails Market Share (%) in Terms of Value, by Type, 2021
Increasing prevalence of infectious diseases is expected to drive the market growth during the forecast period.
The increasing prevalence of various infectious diseases such as COVID-19 is expected to drive the market growth during the forecast period. For instance, according to the World Health Organization Coronavirus (COVID-19) dashboard, over 396,558,014 cases and 5,745,032 deaths due to coronavirus (COVID-19) were reported as of February 8, 2022, across the globe.
|Base Year:||2020||Market Size in 2021:||US$ 2,113.5 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2021 to 2028|
|Forecast Period 2021 to 2028 CAGR:||10.9%||2028 Value Projection:||US$ 4,363.7 Mn|
Cipla Inc., F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc., Zydus Cadila, AstraZeneca, Aridis Pharmaceuticals Inc., Immunome Inc., Celltrion Healthcare Co.,Ltd., and Eli Lilly and Company
|Restraints & Challenges:||
Figure 2. Global Antibody Cocktails Market Share (%), by Distribution Channel, 2021
Increasing product approvals by the regulatory bodies is expected to drive market growth during the forecast period.
The increasing product approvals for the antibody cocktails therapy by the regulatory bodies is expected to drive growth of the global antibody cocktails market over the forecast period. For instance, in Decemeber 2021, AstraZeneca, a multinational pharmaceutical and biotechnology company received the U.S. Food and Drug Administration emergency use authorization (EUA) for its antibody cocktail Evusheld (tixagevimab co-packaged with cilgavimab and administered together) for the pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and pediatric individuals.
Global Antibody Cocktails Market – Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and lockdowns in various countries across the globe have negatively impacted the financial status of businesses across all sectors. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions.
However, the pandemic has positively impacted the global antibody cocktails market, owing to the increasing research and development activities by the key players to develop antibody cocktails and lower the risk of hospitalization in the case of severe COVID-19 infected patients. For instance, in July 2021, the Brihanmumbai Municipal Corporation (BMC) said that a preliminary experiment of a cocktail of two antibody drugs- Casirvimab and Imdevimab, for the treatment of COVID-19, has been successful. The BMC said that the number of patients requiring oxygen after this cocktail medication was only 0.5% and the mortality rate was reduced by 70%. Earlier, the requirement for hospitalization was 13 to 14 days, which was reduced to 5 to 6 days after administering this antibody cocktail therapy.
Global Antibody Cocktails Market: Restraint
The major factors that hinder growth of the global antibody cocktails market include the high cost of the drugs and stringent government regulations for product approval. For instance, the antibody cocktail therapy REGEN-COV (Casrivimab and Imdevimab) developed by Regeneron Pharmaceuticals Inc., a biotechnology company, is priced at US$ 2,100 per dose in the U.S., US$ 2,000 per dose in Germany and US$ 820 per dose in India.
Major players operating in the global antibody cocktails market include Cipla Inc., F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc., Zydus Cadila, AstraZeneca, Aridis Pharmaceuticals Inc., Immunome Inc., Celltrion Healthcare Co.,Ltd., and Eli Lilly and Company.
An antibody, also called immunoglobulin, is a protective protein produced by the immune system of the body in response to the presence of a foreign substance, called an antigen. Antigens are a wide range of substances that include disease-causing organisms and toxic materials such as insect venom, bacteria, or viruses. An antibody cocktail is basically a combination or cocktail of two different antibodies. The rationale behind combining two antibodies in a cocktail approach is to minimize mutational viral escape.
The increasing adoption of inorganic strategies such as partnerships and agreements by key players in the market is expected to drive the market growth during the forecast period. For instance, in May 2021, F. Hoffmann-La Roche Ltd., a multinational healthcare company, and Cipla Inc., a multinational pharmaceutical company, entered into a strategic partnership by which F. Hoffmann-La Roche Ltd., will import its antibody cocktail (Casirivimab and Imdevimab) medication into India, where it will then be marketed and distributed by the Cipla’s distribution network.
Moreover, in August 2020, F. Hoffmann-La Roche Ltd., a multinational healthcare company, and Regeneron Pharmaceuticals Inc., a biotechnology company, announced that they had agreed to develop, manufacture, and distribute REGN-COV2, Regeneron’s investigational antiviral antibody cocktail, to people around the globe. This collaboration is expected to increase the supply of REGN-COV2 by at least three and a half times the current capacity, with the potential for even further expansion. As a part of this agreement, Regeneron will be responsible for distributing REGN-COV2 in the U.S. and Roche will distribute it outside the U.S., as a part of this agreement.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.